AstraZeneca’s ETCAMAH (camizestrant) combo gains US 1st-line HR+ breast cancer approval
AstraZeneca says ETCAMAH (camizestrant) with a CDK4/6 inhibitor—abemaciclib, palbociclib or ribociclib—has been approved in the US for adult patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer.
AstraZeneca’s ETCAMAH® (camizestrant), used with a cyclin-dependent kinase (CDK) 4/6 inhibitor — abemaciclib, palbociclib or ribociclib — has been approved in the US for adult patients with hormone receptor (HR)-positive, HER2-negative, locally advanced or metastatic breast cancer.